trial

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCTId NCT02642029
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 28 (actual)
Sponsored by Mclean Hospital
Primary completion 2019-06-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2016-02-18
Primary completion
2019-06-14
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Excitatory TMSInhibitory TMS

Sponsors

Mclean HospitalLead Sponsor
Massachusetts General HospitalCollaborator

Investigators

1
Ann K Shinn, MD, MPHPrincipal Investigator

Sites

2 total
Belmont, United StatesCharlestown, United States

Facts & assertions

4 sourced
Enrollment
28
Phase
NA
Primary Completion Date
2019-06-14
Status
COMPLETED
relationships
The graph out of here
drug
Excitatory TMS
drug
Inhibitory TMS
drug
lead_sponsor
Mclean Hospital
company
collaborator
Massachusetts General Hospital
company
indication
Bipolar Disorder I
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Ann K Shinn, MD, MPH
person